Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Total Non-Current Liabilities data on file, last reported at $123.0 million in Q4 2023.

• Quarterly Total Non-Current Liabilities fell 70.54% year-over-year to $123.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $123.0 million (down 70.54% YoY) and the FY2023 annual result came in at $123.0 million, down 70.54% from the prior year.
• Total Non-Current Liabilities grew to $123.0 million in Q4 2023 per DNLI's latest filing, from $118.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $453.0 million in Q4 2020 and bottomed at $118.1 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $295.0 million (2020), against an average of $289.1 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities surged 201.41%; it then tumbled 71.61% in 2023.
• Tracing DNLI's Total Non-Current Liabilities over 5 years: stood at $158.0 million in 2019, then surged by 186.81% to $453.0 million in 2020, then slipped by 2.55% to $441.5 million in 2021, then declined by 5.45% to $417.4 million in 2022, then slumped by 70.54% to $123.0 million in 2023.
• Per Business Quant, the three latest DNLI Total Non-Current Liabilities figures stand at $123.0 million (Q4 2023), $118.1 million (Q3 2023), and $118.5 million (Q2 2023).

Peer Comparison